Id |
Subject |
Object |
Predicate |
Lexical cue |
T29 |
0-175 |
Sentence |
denotes |
Itolizumab is a humanized monoclonal antibody developed at the Center of Molecular Immunology, in Cuba, that recognizes a region in the distal domain of the human CD6 [10,11]. |
T30 |
176-359 |
Sentence |
denotes |
The antibody reduces the expression of the intracellular proteins involved in activation and inhibits the proliferation of T cells, even in the presence of the ALCAM and IL-2 [10–12]. |
T31 |
360-491 |
Sentence |
denotes |
The effect is associated with the reduction of the secretion of pro-inflammatory cytokines including IFN-γ, IL-6 and TNF-α [13,14]. |
T32 |
492-603 |
Sentence |
denotes |
The antibody has demonstrated to be safe and efficacious in patients with moderate to severe psoriasis [15,16]. |
T33 |
604-795 |
Sentence |
denotes |
Studies from blood and tissue samples from patients with severe psoriasis showed that itolizumab reduces the proliferation of T cells and serum concentration of IL-6, TNF-α and IFN-γ [13–16]. |
T34 |
796-880 |
Sentence |
denotes |
A significant reduction of the inflammatory pattern was also observed in the tissue. |
T35 |
881-1130 |
Sentence |
denotes |
On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation. |
T36 |
1131-1278 |
Sentence |
denotes |
The study will be published soon (manuscript accepted) and here we describe in detail the outcome of three initial patients receiving the antibody. |